The AGFG2 Knockout Jurkat Polyclonal Cells consist of a heterogenous pool of human T lymphocyte-derived Jurkat cells with targeted disruption of the AGFG2 gene via CRISPR/Cas9 genome editing. This polyclonal knockout population enables loss-of-function analysis of AGFG2 in a cellular context, facilitating studies of its role in vesicle trafficking, nuclear transport, and host-pathogen interactions without clonal selection bias.
Jurkat cells, derived from an acute T cell leukemia patient, serve as an established model for T cell receptor signaling, lymphocyte activation, and retroviral replication. Their use in immunology and virology, particularly for human immunodeficiency virus type 1 (HIV-1) research, provides a physiologically relevant T lymphocyte environment for examining gene function in leukemic progression and viral assembly.
AGFG2 encodes a GTPase-activating protein (GAP) for ADP-ribosylation factor (ARF) small GTPases, primarily ARF1 and ARF6. By stimulating GTP hydrolysis, AGFG2 inactivates ARF proteins, thereby regulating COPI vesicle formation, endosomal trafficking, actin cytoskeleton remodeling, and mRNA export from the nucleus. AGFG2 directly interacts with HIV-1 Gag polyprotein and nucleoporins, linking ARF signaling to nuclear pore complex dynamics. Upstream activation occurs through growth factor receptors and ARF signaling cascades, while downstream effectors include ARF1/ARF6, phosphatidylinositol 4,5-bisphosphate (PIP2), and phospholipase D (PLD).
In the Jurkat T cell context, AGFG2 knockout disrupts ARF-dependent membrane trafficking pathways critical for HIV-1 Gag targeting to the plasma membrane and virion release. Moreover, abrogating AGFG2 function may alter T cell receptor-mediated signaling and vesicle transport, impacting leukemic cell behavior. This model provides a platform to dissect how ARF GAP activity influences T cell leukemia pathophysiology and virus-host interactions, shedding light on potential therapeutic targets.
Typical applications include quantitative analysis of HIV-1 replication by p24 ELISA, co-immunoprecipitation assays examining AGFG2?CGag interactions, and vesicle trafficking studies using fluorescence-based approaches. Additional uses encompass flow cytometric evaluation of T cell activation markers, RT-qPCR profiling of ARF pathway components, and nuclear import/export assays. These polyclonal knockout cells are also suitable for cell proliferation and drug response screens in leukemic backgrounds. For further information, please contact Ascent Research.
